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Abstract
Background: Tuberculosis/Human immunodeficiency virus (TB/HIV) co-infection is bidirectional and synergistic
which mainly affects interventions that have been taken on the area. Tb patients co-infected with HIV have poorer
treatment outcome as compared to non-co-infected patients. There is limited information regarding successful TB
treatment outcomes and its associated factors; a reason that this study was planned to investigate.
Methods: An institution based cross sectional study was carried out from July 2010 to January 2016. Data were
abstracted from patients’ medical chart using data abstraction format. The completeness of the data was checked
and cleaned manually. Then, it was entered and analyzed by using SPSS version 20.0. Bi-variable and Multi-variable
logistic regression model was fitted to identify factors associated with successful Tb treatment outcome. Significance
was obtained through adjusted odds ratio with its 95% CI and a p < 0.05.
Results: Successful TB treatment outcome among TB/HIV co-infected patients in Gondar University Hospital was 77.3%
[95%CI 72.6–81.9]. Being residing in outside the Gondar town [AOR = 0.44, 95%CI: 0.25–0.80], having less than the mean
baseline weight (<43.7 kg) at initiation of TB treatment [AOR = 0.51, 95% CI: 0.29–0.89], being in the bedridden
condition [AOR = 0.23, 95% CI: 0.1–0.23], and experiencing anti-TB treatment side effect [AOR = 0.35, 95% CI: 0.12–0.98]
were the factors that resulted the patient in treatment failure.
Conclusion: Successful Tb treatment outcome among TB/HIV co-infected patients was lower than the target set by
Global Plan to Stop TB 2011–2015. Strengthening collaborative TB/HIV management activities that would trace the
identified factors shall be recommended to increase successful treatment outcome of TB.
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Background
Despite various efforts made to prevent and/or control
the disease, many countries have not yet achieved the
TB control targets. Rather, it remains a major public
health problem leading to mortality in high HIV- burden
countries [1, 2]. HIV drives TB epidemic in many coun-
tries, especially in the sub-Saharan Africa, where 82% of
the world’s TB/HIV co-infection exists [3]. TB/HIV co-
infection in one’s body potentiate one another and has-
tening the weakening of the host’s immunological func-
tions. HIV co-infection is the most important risk factor
for developing active TB, which increases susceptibility
to primary infection, re-infection and/or reactivation for
patients with latent TB. TB also has a negative impact
on the immune response to HIV, increasing the progres-
sion from HIV infection to acquired immunodeficiency
syndrome (AIDS) [4].
Tuberculosis/HIV co-infection constitutes several
problems including diagnostic and therapeutic chal-
lenges in the healthcare settings [5–7]. It is supported by
a study conducted in USA that revealed treatment of TB
in co-infected patients differ from those patients who
are infected with TB only [8]. Some of these challenges:
clinical problems about duration of treatment, frequency
of drug administration, pill burden, management of drug
interactions, and complications of therapy like drug tox-
icity and immune reconstitution inflammatory syndrome
(IRIS). Since such patients are being treated for two in-
fectious diseases, the goals of treatment for both must
be balanced through therapy integration, use of concur-
rent Antiretroviral Therapy (ART), prevention of HIV-
related co-morbidities, controlling drug toxicity, and
monitoring of IRIS [2, 4]. This would bring optimal out-
comes in terms of treatment response and prevention of
drug resistance.
Among the 22 high TB burden countries, Ethiopia
ranks 7th with an incidence rate of 379 cases of all forms
of TB per 100,000 populations. Continuous tracing of TB
treatment outcome, mainly in those TB/HIV co-infected
patients, is essential in the area [9, 10]. However, in our
study site, there was scarcity of recent data describing suc-
cessful TB treatment outcome and its associated factors in
TB/HIV co-infected patients [11]. Understanding its treat-
ment outcome and associated factors in such a population
may help in better management of TB. Therefore, this
study assessed the successful TB treatment outcomes and
its associated factors among TB/HIV co-infected patients
attending the TB DOTS Clinic at the Gondar University
Hospital, Northwest Ethiopia.
Methods
Study setting and design
The study was conducted at the Gondar University
Hospital, Northwest Ethiopia, situated 738 kilometers far
away from the capital. The Hospital serves over five mil-
lions of people from its catchment area (Amhara National
Regional State Bureau of Health, Health Research Thematic
Areas of Amhara Regional Health Bureau: Amhara
Regional Health Bureau Health Research and Technology
Transfer Core Process in collaboration with Ethiopian
Network for HIV/AIDS Treatment Care and Support
(ENHAT-CS) Amhara Region Program, Unpublished).
An instituttion based cross-sectional analysis of successful
TB treatment outcome among TB/HIV co-infected
patients registered from July 2010 to January 2016
was conducted.
Gondar University hospital uses different types of
TB diagnostic techniques like AFB microscopy or
smear, X-ray, pathological, and Xpert MTB/RIF as required
procedurally. TB DOTS clinic serves both adult and
pediatric age groups with free drugs like Rifampicin,
Isoniazid, Pyrazinamide and Ethambutol (2RHZE) for 2
months intensive phase with daily observation, and
Rifampicin and Isoniazid (4RH) for 4 months continuous
phase with monthly follow up for new TB patient. The
hospital also provides Rifampicin, Isoniazide, Pyrazinamide,
Ethambutol and Streptomycin (3RHZES) for 3 months in-
tensive phase/, and Rifampicin, Isoniazide and Ethambutol
(5RHE) for 5 months continuous phase for retreatment pa-
tients. For TB/HIV co-infected patients; they should take
daily for 6 months; 2 months intencive phase taking Rifam-
picin, Isoniazid, Pyrazinamide and Ethambutol (2RHZE)
and 4 months continuation phase taking Rifampicin and
Isoniazid (4RH).
All Tb patients under treatment follow up were tested
for HIV. For HIV screening, nationally approved rapid
serological testing algorisms (KHB→ StatPak→Uni-gold)
were used. As soon as HIV is identified in a TB patient,
the patient is enrolled to ART clinic and co-trimoxazole
preventive therapy (CPT) started. The national TB/HIV
implementation guideline recommends provision of ART
for TB/HIV co-infected individuals if they are WHO clin-
ical stage IV or CD4 < 350/mm.
Study population and sampling procedure
The study population was all TB/HIV co-infected pa-
tients who attended at the Gondar University Hospital.
TB/HIV co-infected patients who were transferred out
to other health institution during the study period were
excluded. The necessary sample size (n) was computed
by single population proportion formula ([n = [(Za/2)
2*P
(1-P)]/d2]) assuming 95% confidence level of Z a/2 =
1.96, 5% margin of error, and proportion (p) of 70.9%
according to the previous similar study from Tigray
region [12]. The calculated sample was 318 and by
using correction formula the final sample size was reduced
to 203. However, all TB/HIV co-infected patients’ rec-
ord at the Gondar University Hospital who started
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DOTs and had complete medical records on TB treat-
ment outcome in the past 5 years were included in
the study.
Data collection and variable measurement
Data were collected using pre-tested and updated data
abstraction format. The format was developed by con-
sidering variables to be studied that found in the pa-
tient’s TB/HIV treatment follow up chart and/or hospital
registration book. Data collectors had a brief training
that emphasized on inclusion and exclusion criteria of
the study participants, and recording of the right infor-
mation from the hospital registration book and/or pa-
tient’s follow-up medical chart.
Clinical case and treatment outcome definitions were
used according to the standard definitions of National
Tuberculosis and Leprosy Control Program (NTLCP)
[12] and WHO guideline [13]. Treatment outcomes were
divided into (cured, completed treatment, defaulted/
interrupted, failed, died, and not evaluated). Successful/
favorable/good outcome were considered for TB patients
who were cured (i.e., negative smear microscopy at the
end of treatment and on at least one previous follow-up
test) and/or completed treatment or sum of cases that
cured and completed treatment [14].
Unsuccessful/unfavorable/poor outcome was consid-
ered for TB patients resulted in treatment failure, default
or death [14]. Patients with documented treatment com-
pletion and resolution of symptoms, but not sputum
smear microscopy available at the end of treatment were
considered as completed treatment. Defaulted/Interrupted
patient was a patient whose treatment was interrupted for
two consecutive months or more for any reason without
medical approval.
Patients with clinical and/or bacteriological signs of
continued active disease or deterioration requiring a
treatment change were considered as failed patients.
Died patient is a patient who died for any reason during
the course of treatment. A patient whose treatment out-
come is unknown (including former “transfer out”) was
considered as not evaluated patients. A Patient who
smoked at time of TB diagnosis or had history of
cigarette smoking were taken as smokers and a patient
who had never smoked in his/her life [15, 16] were taken
as non-smokers.
Functional status was determined based on WHO
guideline as follows; (a) Working = able to perform usual
work in or out of the house, harvest, go to school or, for
children, normal activities or playing (b) Ambulatory =
able to perform activities of daily living but not able to
work or play, and (c) Bedridden = not able to perform
activities of daily living. Tb treatment side effect was
ascertained by assessing and/or following of the patients’
complain, and a comprehensive clinical history and
additional medical exams along with different laboratory
investigations including chemistry and hematocrit
analysis.
Socio-demography of the patient (age, sex, eco-
nomic status), concomitant condition (World Health
Organization clinical staging, functional status), Biological
factor (CD4+ Count), Patient Behavior (Smoking history),
and medication related factor (History of TB treatment,
drug side effect, ART) were collected as an independent
variables of the study.
Data quality
Data abstraction checklist was pre-tested at Felege
Hiwot Referral Hospital, which provides similar services
to the TB/HIV co-infected patients prior to the com-
mencement of the actual data collection. Data were
collected by the trained data collectors with close super-
vision and assistant of the investigators. Completeness of
the data was checked, coded and entered into the com-
puter using SPSS version 20 statistical software on a
daily basis. Each entry was cross checked independently
to ensure the quality of data.
Data analysis
A total of 324 TB/HIV co-infected patients were primarily
enrolled in the study. Of this figure, 308 patients fulfilled
the inclusion criteria and were analyzed. Descriptive statis-
tics (mean (SD), proportion) aimed to summarize patients’
characteristics across the outcome variables was used.
Findings were described using words and tables. Associ-
ation between successful TB treatment outcomes and
each independent variable was analyzed using Bi-variable
and Multi-variable logistic regression model.
The outcome was categorized as successful (cure +
treatment completed) and unsuccessful (default, failure,
death) treatment outcomes [14, 17]. All variables were
entered into multivariable logistic regression using back-
ward LR method to control confounding effect. Explana-
tory variables which had significant association with the
outcome at p-value less than 0.2 in the bi-variable binary
logistic regression were entered to multivariable logistic
regression model to identify the predictors of successful
Tb treatment outcome. Association between outcome
and predictor variables was calculated using Adjusted
odds ratio at p-value <0.05 and 95% confidence interval.
Assumption of goodness of the model was checked by
Hosmer-lemeshow test (p = 0.828).
Ethical consideration
Ethical approval was obtained from the Ethical Clearance
Committee of the School of Medicine, College of
Medicine and Health Sciences, University of Gondar prior
to the commencement of the study. Confidentiality of the
participants’ information was maintained by giving
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participant’s code number and the data locked in the cup-
board and computer with password.
Results
Socio-demographic and behavioral characteristics of
study participants
A total of 308 TB/HIV co-infected patients record were
analyzed in this study. Of these, 175 (56.8%) were male.
The mean age of the respondents was 31.7 (SD ± 13.4)
year. Two hundred and twenty nine (74.4%) study par-
ticipants were residing in the Gondar town, and
206(66.9%) were ever married (married, divorced, or
widowed) during their visits of the health institution.
One hundred thirty three (43.2%) had primary educa-
tional level (Grade 1 to 8th), 97(31.5%) were daily la-
borer, and 264(85.7%) had no history of cigarette
smoking (Table 1).th=tlb=
Concomitant, biological and medication related factors of
the study participants
One hundred and ninety five (63.3%) respondents had
<200 CD4 cell/mm3 at initiation of their TB treatment.
The mean baseline weight at entry of TB treatment was
43.7 kg. Six hundred sixty three (52.9%) of the study
participants have been found to be on working func-
tional status. Two hundred seventy four patients (88.9%)
were on Co-trimoxazole Prophylactic Treatment (CPT),
188(61.0%) on ART, and 188(61.0%) were categorized as
WHO clinical stage III during the initiation of their TB
treatment. In addition, 231(75.0%) respondents had not
history of TB treatment, 219(71.1%) had Pulmonary tu-
berculosis (PTB), and 290(94.2%) had no TB treatment
side effects (Table 2).
Successful TB treatment outcome of the study
participants
As shown in Table 3, of the 308 TB/HIV co-infected pa-
tients who were included in this study, 238 (77.3%) (95%
CI 72.6–81.9) had successful TB treatment outcome, in
which, 32(10.4%) and 206(66.9%) have been cured and
completed their TB treatment respectively (Table 3).
Factors associated with successful TB treatment outcome
of the study participants
In the Multi-variable logistic regression analysis; resi-
dence, mean baseline weight (kg), functional status, and
TB treatment side effect of the respondents were signifi-
cantly associated with the successful TB treatment out-
come (P < 0.05).
Accordingly, the odds of having successful Tb treat-
ment outcome was 66% lower among TB/HIV co-
infected patients who have been residing outside the
Gondar town as compared to those who have been living
in the Gondar town [AOR = 0.44, 95% CI: 0.25–0.80].
The Odds of having successful TB treatment outcome
among TB/HIV co-infected patients having the mean
base line weight <43.7 kg was 49% lower as compared to
patients who had ≥ 43.7 kg at the initiation of their TB
treatment [AOR = 0.51, 95% CI: 0.29–0.89]. Similarly,
the Odds of having successful TB treatment outcome was
77% lower among patients on bed ridden as compared to
patients on working condition[AOR = 0.23, 95% CI: 0.1–
0.23]. Lastly, the odds of successful TB treatment outcome
was 65% times lower among Tb/HIV co-infected patients
who complained TB treatment side effects than their
counterparts [AOR = 0.35, 95% CI: 0.12–0.98] (Table 4).
Discussion
Tuberculosis and HIV co-infection is one of the most
public health challenges in sub-Saharan Africa [18]. It is
Table 1 Socio-demographic and behavioral characteristics of
respondents, Gondar University Hospital, 2016
Variables Categories Frequency of TB treatment
outcome, n (%)
Total Successful,
n (%)
Unsuccessful
Sex Male 175 136 (77.7) 39 (22.3)
Female 133 102(76.7) 31(23.3)
Age (years) <15 42 29(69.1) 13(30.9)
15–29 81 70(77.8) 20(22.2)
30–44 137 107(78.1) 30(21.9)
>44 48 30(81.1) 7(18.9)
Residence Gondar town 229 186(81.2) 43(18.8)
Out of Gondar
town
79 52(65.8) 27(34.2)
Marital status Ever married 206 164(79.6) 42(20.4)
Unmarried 57 42(73.7) 15(26.3)
Not applicable 45 32(71.1) 13(28.9)
Education No education 60 49(81.7) 11(18.3)
Primary 133 97(72.9) 36(27.1)
Secondary and
above
100 82(82.0) 18(18.0)
Not specified/NA) 15 10(66.7) 5(33.3)
Occupation Farmer 27 20(74.1) 7(25.9)
Merchant 46 31(67..4) 15(32.6)
Housewife 43 37(86.0) 6(14.0)
Student 37 27(73.0) 10(27.0)
Employed 43 34(79.1) 9(20.9)
Daily laborer 97 80(82.5) 17(17.5)
Note specified 15 9(60.0) 6(40.0)
Cigarette
smoking
Non-smoking
history
264 206(78.0) 58(22.0)
Smoking history 19 15(58.9) 4(21.1)
Not specified 25 17(68.0) 8(32.0)
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recognized that both TB and HIV contributes to each
other’s progress [19] that affects the successful outcome
of TB treatment, which ranges from 28.9% in Ethiopia
[20] to 84.17% in India [21] and 86.0% in Malawi [22].
The overall successful TB treatment outcome in this
study was 77.3%. This result is higher than studies
conducted in India 67.2% [23], Iran 64.0% [24], Malaysia
53.4% [25], Ghana 64.0% [26], Nigeria 48.8% [27] and
62.7% [28], and Ethiopia 28.9% [20], 60.7% [29], 70.8%
[17]. The possible explanation for this discrepancy might
be associated with the difference in number of study
participants involved in the study. On top of that, the
handling of transfer out cases as one of the case defin-
ition of the TB treatment outcome in various studies in-
dicated earlier may have also an effect on the reduction
of the successful treatment outcome. But, in our cases,
we did not include transferred out as one of the TB
treatment outcome. Successful Tb treatment outcome
may also be affected by the presence of more deaths
and/or defaulters. It is evidenced by the studies con-
ducted in Ethiopia where 11.4% transferred out, 10.0%
defaulters and 17.4% deaths were recorded [29]; in
Malaysia, 25.6% of the study participants were defaulters
and the other 21.0% were death [25], which accounted a
total of 46.6%.
Table 2 Concomitant, biological and medication related factors of the study participants, University of Gondar, 2016
Total Tb treatment outcome, n (%)
Variables/factors Categories N = 308 Successful Unsuccessful
CD4+ count at TB treatment entry <200 cells/mm2 195 149(76.4) 46(23.6)
≥200 cells/mm2 113 89(78.8) 24(21.2)
Mean base line weight (kg) at TB treatment entry <43.7 132 92(69.7) 40(30.3)
≥43.7 176 146(83.0) 30(17.0)
Functional status Working 163 136(83.4) 27(16.7)
Ambulatory 88 74(84.1) 14(15.9)
Bedridden 57 28(49.1) 29(50.9)
INH prophylaxis Yes 12 10(83.3) 2(16.7)
no 296 228(77.0) 68(23.0)
CPT Yes 274 214(78.1) 60(21.9)
no 34 24(70.6) 10(29.4)
ART at TB treatment entry pre-ART 188 143(76.1) 45(23.9)
on ART 120 95(79.2) 25(20.8)
WHO staging III 188 154(81.9) 34(18.1)
IV 120 84(70.0) 36(30.0)
TB treatment history Yes 77 59(76.6) 18(23.4)
No 231 179(77.5) 52(22.5)
TB type Pulmonary 219 175(79.9) 44(20.1)
Extra-pulmonary TB 89 63(78.8) 26(29.2)
Category(case definition) of TB New TB cases 221 169(76.5) 52(23.5)
Relapse cases 48 37(77.1) 11(22.9)
Transfer in 39 32(82.1) 7(17.9)
Smear status (n = 219) Positive 47 38(80.9) 9(19.1)
Negative 172 133(77.3) 39(22.7)
Treatment side effect Yes 18 10(55.6) 8(44.4)
No 290 228(78.6) 62(21.4)
Table 3 TB treatment outcome of the study participants,
University of Gondar, 2016
TB treatment outcome Categories Frequencies (n) Percent (%)
Successful outcome - 238 77.3
Cured 32 10.4
Completed 206 66.9
Unsuccessful outcome - 70 22.7
Defaulted 37 12.0
Failed 2 0.6
Death 31 10.1
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The successful TB treatment outcome which we found
in the current study is nearly in agreement with studies
conducted in Asian countries like in Indian; 75.0% [30],
79.0% [31], and 80.0% [32]; in Vietnam 74.0% [33]; in
Africa, Zambia 80.0% [34] and Ethiopia 80.5% [35].
However, it is lower than the target of successful TB
treatment outcome (85%) recommended by the WHO
[9]. Furthermore, the successful outcome of TB
treatment found in India was 84.17% [21], Malawi 86%
[22]; and in South Africa 82.2% [36] which are higher
than the outcome we found in the current study. Of
course, the current finding showed substantial improve-
ment compared to the two studies conducted in Ethiopia
that ranges from 28.9 to 70.8% [17, 20].
The variation between our finding and results of
others might be due to the presence of TB and HIV
Table 4 Bi-variable and multi-variable logistic regression analysis of factors associated with TB treatment outcome of the study
participants, University of Gondar, 2016
Variable Categories TB Treatment outcome, n = 308 COR (95% CI) AOR (95% CI)
Successful Unsuccessful
Sex Male 136 39 1
Female 102 31 0.94 (0.55, 1.61)
Age <15 29 13 0.45 (0.16, 1.22)
15–29 59 22 0.54 (0.22, 1.32)
30–44 110 27 0.82 (0.34, 1.94)
>44 40 8 1
Residence Urban 186 43 1 1
Rural 52 27 0.45 (0.25, 0.79) 0.44 (0.25, 0.80) *
Educational status No education 49 11 1
Primary 97 36 0.61 (0.28, 1.29)
Secondary and above 82 18 0.10 (0.45, 2.34)
Not specified/NA) 10 5 0.45 (0.13, 1.58)
Marital status Ever married 164 42 1
Unmarried 42 15 0.72 (0.36, 1.42)
Not specified 32 13 0.63 (0.30, 1.31)
CD4 at TB Rx <200 cells/mm3 149 46 1
≥200 cells/mm3 89 24 1.15 (0.66, 2.00)
Mean baseline weight (Kg) <43.7 92 40 0.47 (0.28–0.81) 0.51(0.29–0.89) *
>/=43.7 146 30 1 1
Functional status Working 136 27 1 1
Ambulatory 74 14 1.05 (0.52, 2.12) 1.29(0.62, 2.67)
Bedridden 28 29 0.19 (0.09, 0.37) 0.24 (0.12, 0.48)*
CPT Yes 214 60 1
No 24 10 0.67 (0.31, 1.49)
ART Pre-ART 143 45 1
On ART 95 25 1.19 (0.69, 2.08)
WHO stage III 154 34 1
IV 84 36 0.52 (0.30, 0.88)
TB treatment history Yes 59 18 0.95 (0.52, 1.76)
No 179 52 1
TB type Pulmonary 175 44 1
Extra-pulmonary 63 26 0.61 (0.35, 1.07)
TB Treatment side effect Yes 10 8 0.34 (0.13, 0.89) 0.35 (0.12, 0.98) *
No 228 62 1 1
*significant at p-value <0.05
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drug-drug interaction, patient’s awareness on importance
of adhering to TB treatment, and availability of facilities
used to screen or diagnose TB in HIV/AIDS patients. In
addition, a patient who is on TB-ART co-treatment will
have higher pill burden and most likely will experience
more side effects compared to those patients who are in-
fected with TB only. These factors may lead to have low
adherence to anti-TB drugs [37]. In addition, the sub-
stantial figures of defaulters and death recorded, and
socio-economic conditions of the society in our cases
may contribute for the low treatment outcome. These
may support the reasons for many countries that are
failing to achieve adequate successful TB treatment
outcomes.
Being residing in the Gondar town is found to be sig-
nificantly associated with the successful TB treatment
outcome in our study which is in line with a study con-
ducted in the same country [17, 38]. The possible ex-
planation for this condition is that being residing in the
town might be positively associated with TB notification
[39, 40] which lead to the successful TB treatment out-
come of the patients. Secondly, it is evidenced by a study
conducted in Jimma, Ethiopia, where a rural resident
had lower TB treatment outcome [41]. In addition, a
better awareness and information about TB and HIV/
AIDS might be more in the town than outside. Lastly,
availability of health institutions at near to the vicinity in
the town and fear of stigma and discrimination in
outside of the town might be contributed for the suc-
cessfulness as well as unsuccessfulness of TB treatment
outcome.
Our finding revealed the presence of a significant asso-
ciation between mean baseline body weight < 43.7 kg
measured at the commencement of TB treatment and
the unsuccessful of TB treatment outcome. It is sup-
ported by a finding reported in Sothern Ethiopia in
which survival of TB patients is lowered when one is
HIV positive and has low baseline body weight during
the initiation of TB treatment [1]. Another two studies
conducted in Ethiopia also supported our finding, in
which lower body weight of the patients at the initiation
of TB treatment was significantly associated with un-
successful outcome of TB treatment [42], and body
weight at the initiation of TB treatment (<35 kg) was
a significant risk factor for death at the time of TB
treatment [43].
Like documented in the literature [35], finding of this
study also showed that those co-infected patients who
were on bedridden is significantly associated with the
unsuccessful TB treatment outcome compared to those
who were in playing and/or working (or active) condi-
tion. It is also consistent with a study conducted in Bair
Dar, Ethiopia where more TB/HIV co-infected bedridden
patients had unsuccessful TB treatment outcome or an
increased risk of mortality during TB treatment [2]. In
addition, as indicated in various literatures, being in bed
ridden condition of the functional status among TB/HIV
co-infected patients demonstrated unsuccessful TB
treatment outcome [41, 44].
The possible explanation for this might be AIDS pa-
tients are likely to become malnourished from con-
stantly being sick, from diarrhea that prevents
absorption of nutrients, from loss of appetite and sores
of mouth that make eating difficult, and from opportun-
istic infections. Similarly, weight loss and bedridden in
TB patients might be explained partly by the loss of ap-
petite and loss of energy by the disease itself and being
immovable or inactive. Those patients who are in the
very low body weight and bed ridden might be unable to
work and care for themselves, live at home, and requires
varying amount of assistance which may equivalent to
institutional or hospital care from others and may lead
to the progression of severity of diseases and even to
death.
In this study, patients who had treatment side effect
showed unsuccessful TB treatment outcome compared
to those who had not experience the treatment side ef-
fect. This is in line with various studies in which they
found that being co-infected with TB/HIV is significantly
associated with unsuccessful treatment outcome [45, 46].
The possible reason could be related to pill burden, in-
crease in adverse effect, drug-to-drug interaction, and
drug induced toxicity, which reduces the adherence of the
patients to their TB treatment regimen.
Apart from such important findings, this study is not
without limitation. As common for secondary data based
studies, important variables like CD4 level, distance to
the health facility, and weight of the patients were in-
complete from the records other than the baseline mea-
sures. In addition, this study may suffer from low sample
size because of lack of complete patients’ medical
record.
Conclusion
This study showed that the successful anti-TB treatment
outcome among TB/HIV co-infected patients who
attended their treatment at the Gondar University
Hospital TB DOTS clinic was below the target set by
World Health Organization (WHO). Being residing in
the Gondar town, having baseline body weight above the
mean, able to perform usual work in or out of the house,
and being free of treatment side effects were found to be
factors associated with successful TB treatment out-
come. Thus, we recommended that strengthening the
integration of TB/HIV collaborative activities could im-
prove the treatment outcome. In addition, improvise
means of TB patients’ follow up and tracing to keep
them in contact with health professionals at service
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delivery point during treatment could increase the suc-
cessfulness of TB treatment outcome.
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